Document and Entity Information |
9 Months Ended |
|---|---|
Sep. 30, 2017 | |
| Document Information [Line Items] | |
| Document Type | 6-K |
| Amendment Flag | false |
| Document Period End Date | Sep. 30, 2017 |
| Document Fiscal Year Focus | 2017 |
| Document Fiscal Period Focus | Q3 |
| Trading Symbol | ICLR |
| Entity Registrant Name | ICON PLC |
| Entity Central Index Key | 0001060955 |
| Current Fiscal Year End Date | --12-31 |
| X | ||||||||||
- Definition If the value is true, then the document is an amendment to previously-filed/accepted document. No definition available.
|
| X | ||||||||||
- Definition End date of current fiscal year in the format --MM-DD. No definition available.
|
| X | ||||||||||
- Definition This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No definition available.
|
| X | ||||||||||
- Definition This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. No definition available.
|
| X | ||||||||||
- Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". No definition available.
|
| X | ||||||||||
- Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Trading symbol of an instrument as listed on an exchange. No definition available.
|
| X | ||||||||||
- Definition Noncurrent capital government grants, which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
- Definition Other undenominated capital. No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of noncurrent assets classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Condensed Consolidated Balance Sheets (Parenthetical) - € / shares |
Sep. 30, 2017 |
Dec. 31, 2016 |
|---|---|---|
| Ordinary shares, par value | € 0.06 | € 0.06 |
| Ordinary shares, shares authorized | 100,000,000 | 100,000,000 |
| Ordinary shares, shares issued | 54,152,200 | 54,530,843 |
| Ordinary shares, shares outstanding | 54,152,200 | 54,530,843 |
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Revenue: | ||||
| Gross revenue | $ 596,169 | $ 622,261 | $ 1,766,016 | $ 1,754,491 |
| Reimbursable expenses | (155,846) | (202,060) | (462,716) | (523,138) |
| Net revenue | 440,323 | 420,201 | 1,303,300 | 1,231,353 |
| Costs and expenses: | ||||
| Direct costs | 259,672 | 243,244 | 760,175 | 709,831 |
| Selling, general and administrative expense | 79,433 | 81,235 | 241,655 | 242,192 |
| Depreciation and amortization | 16,280 | 14,543 | 45,123 | 44,120 |
| Restructuring | 4,065 | 7,753 | 8,159 | |
| Total costs and expenses | 355,385 | 343,087 | 1,054,706 | 1,004,302 |
| Income from operations | 84,938 | 77,114 | 248,594 | 227,051 |
| Interest income | 632 | 462 | 1,766 | 1,155 |
| Interest expense | (3,177) | (3,227) | (9,535) | (9,640) |
| Income before provision for income taxes | 82,393 | 74,349 | 240,825 | 218,566 |
| Provision for income taxes | (8,239) | (10,470) | (30,445) | (30,649) |
| Net income | $ 74,154 | $ 63,879 | $ 210,380 | $ 187,917 |
| Net income per Ordinary Share: | ||||
| Basic | $ 1.37 | $ 1.15 | $ 3.89 | $ 3.39 |
| Diluted | $ 1.35 | $ 1.13 | $ 3.84 | $ 3.33 |
| Weighted average number of Ordinary Shares outstanding: | ||||
| Basic | 54,109,566 | 55,734,773 | 54,110,022 | 55,355,020 |
| Diluted | 54,756,184 | 56,645,239 | 54,840,112 | 56,475,319 |
| X | ||||||||||
- Definition Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Cost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense for debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Accrued Interest On Short Term Bank Deposits No definition available.
|
| X | ||||||||||
- Definition Amortization Of Gain On Interest Rate Hedge No definition available.
|
| X | ||||||||||
- Definition Payments for Share Repurchase Costs No definition available.
|
| X | ||||||||||
- Definition Amortization of Government Grants. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of amortization expense attributable to debt issuance costs. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred income tax expense (benefit) and income tax credits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in current liabilities classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in noncurrent assets classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in noncurrent operating liabilities classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in receivables classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in prepaid expenses, and assets classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow to reacquire common stock during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Adjustment to Retained Earning Share Repurchase costs No definition available.
|
| X | ||||||||||
- Definition Adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
- Definition Tax impact on the adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption. No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Value of stock issued as a result of the exercise of stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of shares that have been repurchased and retired during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Basis of Presentation |
9 Months Ended |
|---|---|
Sep. 30, 2017 | |
| Basis of Presentation |
1. Basis of Presentation
These condensed consolidated financial statements which have been
prepared in accordance with United States Generally Accepted
Accounting Principles (“US GAAP”) have not been
audited. The condensed consolidated financial statements reflect
all adjustments, which are, in the opinion of management, necessary
to present a fair statement of the operating results and financial
position for the periods presented. The preparation of the
condensed consolidated financial statements in conformity with US
GAAP requires management to make estimates and assumptions that
affect reported amounts and disclosures in the condensed
consolidated financial statements. Actual results could differ from
those estimates.
The condensed consolidated financial statements should be read in
conjunction with the accounting policies and notes to the
consolidated financial statements included in ICON’s Form
20-F for the year ended December 31, 2016. Operating results for
the three and nine months ended September 30, 2017, are not
necessarily indicative of the results that may be expected for the
fiscal period ending December 31, 2017.
|
| X | ||||||||||
- Definition The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Goodwill |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
2. Goodwill
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Combinations |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations |
3. Business Combinations
Acquisitions – Mapi Group.
On July 27, 2017, a subsidiary of the Company, ICON Clinical
Research Limited, acquired Mapi Development SAS ('Mapi'). Mapi is a
leading patient-centered health outcomes research and
commercialization company. Cash outflows on acquisition were $144.1
million.
The acquisition of Mapi has been accounted for as a business
combination in accordance with FASB ASC
805 Business
Combinations. The Company has made a provisional assessment
of the fair value of assets acquired and liabilities assumed as at
that date. The table following summarizes the Company’s
provisional estimates of the fair values of the assets acquired and
liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in late phase commercialization, analytics, real
world evidence generation and strategic regulatory services in
clinical trial services for biologics, drugs and devices.
**The Company has made an initial estimate of separate intangible
assets acquired of $30.6 million, being customer relationships and
order book assets. This assessment is under review and will
be finalized within 12 months of the date of acquisition.
Acquisitions – Clinical Research Management, Inc.
On September 15, 2016, a subsidiary of the Company, ICON US
Holdings Inc. acquired ClinicalRM resulting in an initial net cash
outflow of $52.4 million inclusive of certain payments made on
behalf of ClinicalRM totaling $9.2 million.
ClinicalRM is a full-service CRO specializing in preclinical
through Phase IV support of clinical research and clinical trial
services for biologics, drugs and devices. The organization helps
customers progress their products to market faster with a wide
array of research, regulatory and sponsor services within
the U.S. and around the globe. ClinicalRM provide full
service and functional research solutions to a broad range of US
government agencies. Their extensive expertise extends across basic
and applied research, infectious diseases, vaccines development and
testing and the response to bio-threats. They have worked in
collaboration with government and commercial customers to respond
to the threat of global viral epidemics. Further consideration of
up to $12.0 million is payable if certain performance milestones
are achieved in respect of periods up to December 31, 2017.
The fair value of the contingent consideration on acquisition and
at March 31, 2017, was estimated at $6 million. The
evaluation of the performance and forecast performance of
ClinicalRM against performance milestones was updated as required
at June 30, 2017. Arising from that evaluation, the fair
value of the contingent consideration liability was determined as
$Nil, resulting in a net credit of $6 million being recorded within
selling, general & administrative expenses in the Statement of
operations.
The acquisition of ClinicalRM has been accounted for as a business
combination in accordance with FASB ASC
805 Business
Combinations. The table following summarizes the fair values
of the assets acquired and liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in preclinical through Phase IV support of clinical
research and clinical trial services for biologics, drugs and
devices. Goodwill related to the US portion of the business
acquired is tax deductible.
Acquisitions - PMG
On December 4, 2015, a subsidiary of the Company, ICON Clinical
Research LLC. acquired PMG for total cash outflows of $65.4
million, including certain payments made on behalf of PMG totaling
$10.1 million. PMG is an integrated network of 52 clinical research
sites in North Carolina, South Carolina, Tennessee, Illinois and
Iowa. The site network includes wholly owned facilities and
dedicated clinical research sites. PMG conducts clinical trials in
all major therapeutic areas and has particular expertise in
vaccine, gastroenterology, cardiovascular, neurology and
endocrinology studies. It has a proprietary database of clinical
trial participants. It also has access to in excess of
2 million active patients via electronic medical records through
its partnerships with healthcare institutions and community
physical practices.
The acquisition of PMG has been accounted for as a business
combination in accordance with FASB ASC
805 Business
Combinations. The table following summarizes the fair
values of the assets acquired and liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development. In finalizing the goodwill on
acquisition of PMG in the twelve month period from acquisition,
fair value adjustments of $7.7 million were made to deferred tax
liabilities ($3.1 million), accounts receivable acquired ($1.4
million), other liabilities ($1.2 million) and the value of the
customer list and order backlog assets acquired ($0.4
million). Additional consideration of $1.6 million was
provided on completion of the contractual working capital
process.
Acquisitions - MediMedia Pharma Solutions
On February 27, 2015, a subsidary of the Company, ICON Holdings
Unlimited Company (formerly ICON Holdings), acquired MediMedia
Pharma Solutions for cash consideration of $104.8 million (net of
working capital adjustments of $3.9 million). In addition to the
cash consideration, certain payments were made on behalf of
MediMedia Pharma Solutions on completion totaling $11.3 million.
Headquartered in Yardley, Pennsylvania, MediMedia Pharma Solutions
includes MediMedia Managed Markets and Complete Healthcare
Communications. MediMedia Managed Markets is a leading provider of
strategic payer-validated market access solutions. Complete
Healthcare Communications is one of the leading medical and
scientific communication agencies working with medical affairs,
commercial and brand development teams within life science
companies. The acquisition agreement also provided for certain
working capital targets to be achieved by MediMedia Pharma
Solutions.
The acquisition of MediMedia Pharma Solutions has been accounted
for as a business combination in accordance with FASB ASC
805 Business
Combinations. The table following summarizes the fair values
of the assets acquired and liabilities assumed on
acquisition:
*Goodwill represents the acquisition of an established workforce
with experience in the provision of strategic payer-validated
market access solutions while the acquisition of Complete
Healthcare Communications comprises an established workforce with
significant communication experience working with medical affairs,
commercial and brand development teams within the life science
industry. Goodwill related to the US portion of the business
is tax deductible.
** Payments made at acquisition date of $11.3 million were in
respect of certain one-time liabilities which have subsequently
been discharged.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Restructuring |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring | 4. Restructuring
Restructuring charges
A restructuring charge of $7.8 million was recognized during the
nine months ended September 30, 2017, under a restructuring plan
adopted following a review of operations. The restructuring
plan reflected resource rationalization across the business to
improve resource utilization.
Details of the restructuring charge recognized in the three and
nine months ended September 30, 2017, are as follows;
Details of the movement in the restructuring charge recognized in
the three and nine months ended September, 30 2017 are as
follows;
Prior Periods Restructuring charges
A restructuring charge of $8.2 million was recognized during the
year ended December 31, 2016, under a restructuring plan adopted
following a review by the Company of its operations. The
restructuring plan includes resource rationalizations in certain
areas of the business to improve resource utilization, resulting in
a charge of $6.2 million and office consolidation resulting in the
recognition of an onerous lease obligation of $2.0 million during
the twelve months ended December 31, 2016. No additional
charge was recorded during the nine months ended September 30,
2017.
At September 30, 2017, $5.6 million is included within other
liabilities and $0.5 million within non-current other
liabilities.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Income Taxes |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes | 5. Income Taxes
Income taxes recognized during the three and nine months ended
September 30, 2017, comprise:
As at September 30, 2017, the Company maintains a $27.7 million
liability (December 31, 2016: $29.9 million) for unrecognized tax
benefit, which is comprised of $24.1 million (December 31, 2016:
$26.6 million) related to items generating unrecognized tax
benefits and $3.6 million (December 31, 2016: $3.3 million) for
interest and related penalties to such items. The Company
recognizes interest accrued on unrecognized tax benefits as an
additional income tax expense.
The Company has analyzed the filing positions in all of the
significant federal, state and foreign jurisdictions where it is
required to file income tax returns, as well as open tax years in
these jurisdictions. The only periods subject to examination by the
major tax jurisdictions where the Company does business are 2012
through 2016 tax years. The Company does not believe that the
outcome of any examination will have a material impact on its
financial statements.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Net income per ordinary share |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income per ordinary share |
6. Net income per ordinary share
Basic net income per ordinary share has been computed by dividing
net income available to ordinary shareholders by the weighted
average number of ordinary shares outstanding during the period.
Diluted net income per ordinary share is computed by adjusting the
weighted average number of ordinary shares outstanding during the
period for all potentially dilutive ordinary shares outstanding
during the period and adjusting net income for any changes in
income or loss that would result from the conversion of such
potential ordinary shares. There is no difference in net income
used for basic and diluted net income per ordinary share.
The reconciliation of the number of shares used in the computation
of basic and diluted net income per ordinary share is as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Share-based Awards |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Awards |
7. Share-based Awards
Share Options
On July 21, 2008, the Company adopted the Employee Share Option
Plan 2008 (the “2008 Employee Plan”) pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any employee, or any
Director holding a salaried office or employment with the Company
or a Subsidiary for the purchase of ordinary shares. On the same
date, the Company also adopted the Consultants Share Option Plan
2008 (the “2008 Consultants Plan”), pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any consultant, adviser or
non-executive Director retained by the Company or any Subsidiary
for the purchase of ordinary shares.
On February 14, 2017, both the 2008 Employee Plan and the 2008
Consultants Plan (together the “2008 Option Plans”)
were amended and restated in order to increase the number of
options that can be issued under the 2008 Consultants Plan from
400,000 to 1 million and to extend the date for options to be
granted under the 2008 Option Plans.
Each option granted under the 2008 Option Plans will be an employee
stock option, or Non-qualifying Stock Options (‘NSO’),
as described in Section 422 or 423 of the Internal Revenue Code.
Each grant of an option under the 2008 Options Plans will be
evidenced by a Stock Option Agreement between the optionee and the
Company. The exercise price will be specified in each Stock Option
Agreement, however option prices will not be less than 100% of the
fair market value of an ordinary share on the date the option is
granted.
An aggregate of 6 million ordinary shares have been reserved under
the 2008 Employee Plan, as reduced by any shares issued or to be
issued pursuant to options granted under the 2008 Consultants Plan,
under which a limit of 1 million shares applies. Further, the
maximum number of ordinary shares with respect to which options may
be granted under the 2008 Employee Option Plan, during any calendar
year to any employee shall be 400,000 ordinary shares. There
is no individual limit under the 2008 Consultants Plan. No options
may be granted under the 2008 Option Plans after February 14,
2027.
On January 17, 2003, the Company adopted the Share Option Plan 2003
(the “2003 Share Option Plan”) pursuant to which the
Compensation and Organization Committee of the Board could grant
options to officers and other employees of the Company or its
subsidiaries for the purchase of ordinary shares. An aggregate of 6
million ordinary shares were reserved under the 2003 Share Option
Plan; and, in no event could the number of ordinary shares issued
pursuant to options awarded under this plan exceed 10% of the
outstanding shares, as defined in the 2003 Share Option Plan, at
the time of the grant, unless the Board expressly determined
otherwise. Further, the maximum number of ordinary shares with
respect to which options could be granted under the 2003 Share
Option Plan during any calendar year to any employee was 400,000
ordinary shares. The 2003 Share Option Plan expired on January 17,
2013. No new options may be granted under this plan.
Share option awards are granted with an exercise price equal to the
market price of the Company’s shares at date of grant. Share
options typically vest over a period of five years from date of
grant and expire eight years from date of grant. The maximum
contractual term of options outstanding at September 30, 2017 is
eight years.
The following table summarizes option activity for the nine months
ended September 30, 2017:
The Company has outstanding options with fair values ranging from
$8.53 to $25.99 per option or a weighted average fair value of
$11.56 per option. The Company issues ordinary shares for all
options exercised. The total amount of fully vested share options
which remained outstanding at September 30, 2017, was 612,869.
Fully vested share options at September 30, 2017, have an average
remaining contractual term of 3.71 years, an average exercise price
of $39.86 and a total intrinsic value of $45.4 million. The total
intrinsic value of options exercised during the nine months ended
September 30, 2017 was $21.8 million (September 30, 2016: $12.5
million).
The following table summarizes the movement in non-vested share
options for the nine months ended September 30, 2017:
Fair value of Stock Options Assumptions
The weighted average fair value of options granted during the nine
months ended September 30, 2017, and September 30, 2016, was
calculated using the Black-Scholes option pricing model. The
weighted average fair values and assumptions used were as
follows:
Expected volatility is based on the historical volatility of our
common stock over a period equal to the expected term of the
options; the expected life represents the weighted average period
of time that options granted are expected to be outstanding given
consideration to vesting schedules and our historical experience of
past vesting and termination patterns. The risk-free rate is based
on the U.S. government zero-coupon bonds yield curve in effect at
time of the grant for periods corresponding with the expected life
of the option.
Restricted Share Units and Performance Share Units
On July 21, 2008, the Company adopted the 2008 Employees Restricted
Share Unit Plan (the “2008 RSU Plan”) pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may select any employee, or any Director holding
a salaried office or employment with the Company, or a Subsidiary
to receive an award under the plan. An aggregate of 1.0 million
ordinary shares have been reserved for issuance under the 2008 RSU
Plan.
On April 23, 2013, the Company adopted the 2013 Employees
Restricted Share Unit (“RSU”) and Performance Share
Unit (“PSU”) Plan (the “2013 RSU Plan”)
pursuant to which the Compensation and Organization Committee of
the Company’s Board of Directors may select any employee, or
any Director holding a salaried office or employment with the
Company, or a Subsidiary to receive an award under the plan.
On May 11, 2015, the 2013 RSU Plan was amended and restated in
order to increase the number of shares that can be issued under the
RSU Plan by 2.5 million shares. Accordingly, an aggregate of
4.1 million ordinary shares have been reserved for issuance under
the 2013 RSU Plan. The shares are awarded at par value and vest
over a service period. Awards under the 2013 RSU Plan may be
settled in cash or shares at the option of the Company.
The Company has awarded RSUs and PSUs to certain key individuals of
the Group. The following table summarizes RSU and PSU activity for
the nine months ended September 30, 2017:
The fair value of RSUs vested for the nine months ended September
30, 2017, totaled $15.9 million (full year 2016: $10.8
million).
The fair value of PSUs vested for the nine months ended September
30, 2017, totaled $15.0 million (the fair value of PSUs vested for
the full year 2016 was $10.3 million).
The PSUs vest based on service and specified EPS targets over the
period 2014 – 2017, 2015 – 2018, 2016 – 2019 and
2017 – 2020. Since 2013, 274,628 PSUs (net of forfeitures)
have been granted. Up to an additional 262,993 PSUs may also
be granted, based on the actual EPS from 2014 to 2020.
Non-cash stock compensation expense
Non-cash stock compensation expense for the three and nine months
ended September 30, 2017 has been allocated as follows:
Total non-cash stock compensation expense not yet recognized at
September 30, 2017, amounted to $60.6 million. The weighted average
period over which this is expected to be recognized is 2.2
years.
The amendments required by Accounting Standards Update
(‘ASU’) 2016-09 ‘Improvements to Employee
Share-Based Payment Accounting’ require the Company to record
all tax effects related to share-based payments through the income
statement rather than additional paid in capital. The Company has
applied the updated standard prospectively in the first nine months
of the year ended December 31, 2017.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Share Capital |
9 Months Ended |
|---|---|
Sep. 30, 2017 | |
| Share Capital |
8. Share Capital
On October 3, 2016, the Company commenced a previously announced
share buyback program of up to $400 million. The Company can
acquire up to 10% of its outstanding ordinary shares (by way of
redemption), in accordance with Irish law, the United States
securities laws, and the Company’s constitutional documents
through open market share acquisitions.
The buyback program gives a broker authority to acquire the
Company’s ordinary shares from time to time on the open
market in accordance with agreed terms and limitations. The
acquisition of shares pursuant to the buyback program was effected
by way of redemption and cancellation of the shares, in accordance
with the Constitution of the Company.
During the nine months ended September 30, 2017, 1,368,136 ordinary
shares were redeemed by the Company under this buyback program for
a total consideration of $108.1 million. At September 30, 2017 a
total of 2,797,323 ordinary shares were redeemed by the Company
under this buyback program for a total consideration of $218.1
million. All ordinary shares that were redeemed under the buyback
program were canceled in accordance with the Constitution of the
Company and the nominal value of these shares transferred to an
other undenominated capital reserve as required under Irish Company
Law.
|
| X | ||||||||||
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Segment Information |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Segment Information |
9. Business Segment Information
The Company determines and presents operating segments based on the
information that is internally provided to the chief operating
decision maker, together the (‘CODM’) in accordance
with FASB ASC 280-10 Disclosures
about Segments of an Enterprises and Related Information.
The Chief Executive Officer, Chief Financial Officer and Chief
Operating Officer, were together considered the Company’s
CODM in the period up to and including March 1, 2017. On
March 1, 2017, Mr. Ciaran Murray transitioned from his role as
Chief Executive Officer to the role of Executive Chairman of the
Board of Directors and Dr. Steve Cutler was appointed as Chief
Executive Officer. As of March 1, 2017, the Company determined that
the CODM is comprised of the Chief Executive Officer and the Chief
Financial Officer.
The Company determines and presents operating segments based on the
information that is provided to the CODM. The Company has
determined that we operate in one single business segment which is
the provision of outsourced development services on a global basis
to the pharmaceutical, biotechnology and medical devices
industries. There have been no changes to the basis of segmentation
or the measurement basis for the segment results in the
period.
The Company is a contract research organization
(“CRO”), providing outsourced development services on a
global basis to the pharmaceutical, biotechnology and medical
device industries. It specializes in the strategic development,
management and analysis of programs that support all stages of the
clinical development process - from compound selection to Phase
I-IV clinical studies. The Company has the expertise and
capability to conduct clinical trials in most major therapeutic
areas on a global basis and has the operational flexibility to
provide development services on a stand-alone basis or as part of
an integrated “full service” solution. The
Company has expanded predominately through internal growth together
with a number of strategic acquisitions to enhance its expertise
and capabilities in certain areas of the clinical development
process.
The Company is generally awarded projects based upon responses to
requests for proposals received from companies in the
pharmaceutical, biotechnology and medical device industries or work
orders executed under our strategic partnership arrangements.
Contracts with customers are generally entered into centrally, in
most cases with ICON Clinical Research Limited (“ICON
Ireland”), the Company’s principal operating subsidiary
in Ireland. Revenues, which consist primarily of fees earned under
these contracts, are allocated to individual entities within the
Group, based on where the work is performed in accordance with the
Company’s global transfer pricing model.
ICON Ireland acts as the group entrepreneur under the
Company’s global transfer pricing model given its role in the
development and management of the group, it’s ownership of
key intellectual property and customer relationships, its key role
in the mitigation of risks faced by the group and its
responsibility for maintaining the Company’s global network.
ICON Ireland enters into the majority of the Company’s
customer contracts.
ICON Ireland remunerates other operating entities in the ICON Group
on the basis of a guaranteed cost plus mark up for the services
they perform in each of their local territories. The cost plus mark
up for each ICON entity is established to ensure that each of ICON
Ireland and the ICON entities that are involved in the conduct of
services for customers, earn an appropriate arms-length return
having regard to the assets owned, risks borne, and functions
performed by each entity from these intercompany transactions. The
cost plus mark-up policy is reviewed annually to ensure that it is
market appropriate.
The geographic split of revenue disclosed for each region outside
Ireland is the cost plus revenue attributable to these entities.
The residual revenues of the Group, once each ICON entity has been
paid its respective intercompany service fee, generally fall to be
retained by ICON Ireland. As such revenues and income from
operations in Ireland are a function of this global transfer
pricing model and comprise net revenues of the Group after
deducting the cost plus revenues attributable to the activities
performed outside Ireland.
The Company's areas of operation outside of Ireland include the
United States, United Kingdom, Belgium, France, Germany, Italy,
Spain, The Netherlands, Sweden, Turkey, Poland, Czech Republic,
Latvia, Russia, Ukraine, Hungary, Israel, Romania, Switzerland,
Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India,
China, South Korea, Japan, Thailand, Taiwan, Singapore, The
Philippines, Australia, New Zealand, and South Africa.
The geographical distribution of the Company’s segment
measures as at September 30, 2017, and December 31, 2016, and for
the three and nine months ended September 30, 2017, and September
30, 2016, is as follows:
a) The distribution of net revenue by geographical area was as
follows:
* All
sales shown for Ireland are export sales.
b) The distribution of income from operations, including
restructuring, by geographical area was as follows:
c) The distribution of income from operations, excluding
restructuring, by geographical area was as
follows:
d) The distribution of property, plant and equipment, net, by
geographical area was as follows:
e) The distribution of depreciation and amortization by
geographical area was as follows:
f) The distribution of total assets by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
New accounting pronouncements -Revenue from Contacts with Customers |
9 Months Ended |
|---|---|
Sep. 30, 2017 | |
| New accounting pronouncements -Revenue from Contacts with Customers |
10. New
accounting pronouncements –Revenue from Contacts with
Customers
In May 2014, the FASB issued ASU
2014-09, Revenue
from Contracts with Customers (“ASU
2014-09”), which provides that an entity should recognize
revenue to depict the transfer of promised goods or services to
customers in an amount that reflects the consideration to which the
entity expects to be entitled in exchange for those goods or
services. The updated standard will replace most existing revenue
recognition guidance in U.S. GAAP when it becomes effective and
permits the use of either the retrospective or cumulative effect
transition method. To achieve the core principle of the new
standard, an entity should apply the following steps: (1) identify
the contract(s) with a customer; (2) identify the performance
obligations in the contract; (3) determine the transaction price;
(4) allocate the transaction price to the performance obligations
in the contract; and (5) recognize revenue when (or as) the entity
satisfies a performance obligation. Early adoption is
permitted for annual periods beginning after December 16,
2016. Subsequent to issuing ASU 2014-09, the FASB issued the
following amendments concerning clarification of ASU 2014-09. In
March 2016, the FASB issued ASU
2016-08, Revenue
from Contracts with Customers (Topic 606), Principal
versus Agent Considerations (Reporting Revenue Gross versus
Net) (“ASU
2016-08”), which
further clarifies the implementation guidance on principal versus
agent considerations. The new guidance requires either a
retrospective or a modified retrospective approach to adoption. In
April 2016, the FASB issued ASU
2016-10, Revenue
from Contracts with Customers (Topic 606), Identifying Performance
Obligations and Licensing (“ASU
2016-10”), which
clarifies the identification of performance obligations and the
licensing implementation guidance, while retaining the related
principles for those areas. In May 2016, the FASB issued ASU
2016-12, Revenue
from Contracts with Customers (Topic 606): Narrow-Scope
Improvements and Practical
Expedients (“ASU 2016-12”),
which provides clarification on assessing the collectability
criterion, presentation of sales taxes, measurement date for
non-cash consideration and completed contracts at transition.
The updated standard is effective for ICON in the first quarter of
the year ended December 31, 2018. ICON has elected to
adopt the updated standard using the cumulative effect transition
method. Under this transition method, ICON will apply the new
standard as of the date of initial application (i.e. January 1,
2018), without restatement of comparative period amounts.
ICON plc will record the cumulative effect of initially applying
the new standard (to revenue and cost) as an adjustment to the
opening balance of equity at the date of initial application.
Under this method, ICON will apply the requirements of the new
standard to those contracts not completed at the date of initial
application.
While we continue to assess all potential impacts of the new
standard, we believe the most significant impact relates to our
assessment of measurement of performance and percentage of
completion in respect of our clinical trials service
revenue.
Under current GAAP, the revenue attributable to performance is
determined based on both input and output methods of measurement
based on the relationship between hours incurred and the total
estimated hours of the trial, or on the unit of delivery
method. We have evaluated the application of the requirements
of ASC 606 to ‘recognize revenue when or as the entity
satisfies a performance obligation’ to its business. We
have concluded that under the revised standard, clinical trial
service is a single performance obligation satisfied over time i.e.
the full service obligation in respect of a clinical trial
(including services provided by investigators and other parties) is
considered a single performance obligation in respect of the
clinical services revenue stream. Promises offered to
the customer are not distinct within the context of the
contract.
We have also concluded that ICON is the contract principal in
respect of both direct services and in the use of third parties
(principally investigator services) that support the clinical
research project. ICON measure over time performance
obligation considering progress towards completion on an input
measure being total project costs inclusive of third party
costs. The transaction price is determined by reference to
the contract or change order value (total service revenue and
pass-through) adjusted to reflect historical experience to
determine a realizable contract value. Revenue will be
recognized as the single performance obligation is satisfied.
The progress towards completion for clinical service contracts will
be measured based on percentage completion of realizable contract
value at each reporting period.
The revised standard includes additional disclosure requirements
related to revenue. Our results for the first quarter of the
year ended December 31, 2018, being the quarter ended March 31,
2018, will include expanded disclosure in respect of (i)
disaggregated revenue disclosures from contracts with customers
(ii) separate disclosure of contract assets and liabilities (iii)
disclosure of retrospective revenue and (iv) disclosure of the
remaining performance obligations by product/service (or
backlog).
Due to the complexity of certain of our contracts, the actual
revenue recognition treatment required under the new standard for
these arrangements may be dependent on contract-specific terms and
vary in some instances.
|
| X | ||||||||||
- Definition The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Goodwill (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Combinations (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mapi Group [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The table following summarizes the
Company’s provisional estimates of the fair values of the
assets acquired and liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in late phase commercialization, analytics, real
world evidence generation and strategic regulatory services in
clinical trial services for biologics, drugs and devices.
**The Company has made an initial estimate of separate intangible
assets acquired of $30.6 million, being customer relationships and
order book assets. This assessment is under review and will
be finalized within 12 months of the date of acquisition.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clinical Research Management Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The table following summarizes the fair values of the assets
acquired and liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in preclinical through Phase IV support of clinical
research and clinical trial services for biologics, drugs and
devices. Goodwill related to the US portion of the business
acquired is tax deductible.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PMG | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The table following summarizes the fair values of the assets
acquired and liabilities assumed:
*Goodwill represents the
acquisition of an established workforce with experience in clinical
trial consulting and regulatory support for the development of
drugs, medical devices and diagnostics, with a specific focus on
strategy to increase efficiency and productivity in product
development. In finalizing the goodwill on acquisition of PMG in
the twelve month period from acquisition, fair value adjustments of
$7.7 million were made to deferred tax liabilities ($3.1 million),
accounts receivable acquired ($1.4 million), other liabilities
($1.2 million) and the value of the customer list and order backlog
assets acquired ($0.4 million). Additional consideration of
$1.6 million was provided on completion of the contractual working
capital process.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MediMedia Pharma Solutions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The table following summarizes the fair values of the assets
acquired and liabilities assumed on acquisition:
*Goodwill represents the acquisition of an established workforce
with experience in the provision of strategic payer-validated
market access solutions while the acquisition of Complete
Healthcare Communications comprises an established workforce with
significant communication experience working with medical affairs,
commercial and brand development teams within the life science
industry. Goodwill related to the US portion of the business
is tax deductible.
** Payments made at acquisition date of $11.3 million were in
respect of certain one-time liabilities which have subsequently
been discharged.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Restructuring (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Details of Restructuring Charge Recognized |
Details of the restructuring charge recognized in the three and
nine months ended September 30, 2017, are as follows;
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Details of Movement in Restructuring Provisions Recognized |
Details of the movement in the restructuring charge recognized in
the three and nine months ended September, 30 2017 are as
follows;
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring Charges |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Restructuring Charges. No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Income Taxes (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes Recognized During Period |
Income taxes recognized during the three and nine months ended
September 30, 2017, comprise:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Net income per ordinary share (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share |
The reconciliation of the number of shares used in the computation
of basic and diluted net income per ordinary share is as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Share-based Awards (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Stock Option Activity |
The following table summarizes option activity for the nine months
ended September 30, 2017:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Movement in Non-Vested Share Options |
The following table summarizes the movement in non-vested share
options for the nine months ended September 30, 2017:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Weighted Average Fair Values and Assumptions Used |
The weighted average fair values and assumptions used were as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RSU and PSU Activity |
The following table summarizes RSU and PSU activity for the nine
months ended September 30, 2017:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Non-cash Stock Compensation Expense |
Non-cash stock compensation expense for the three and nine months
ended September 30, 2017 has been allocated as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Schedule of Non Cash Stock Compensation Expense. No definition available.
|
| X | ||||||||||
- Definition Schedule Of Share Based Compensation Restricted Stock Units Performance Stock Units Award Activity [Table Text Block] No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of the changes in outstanding nonvested shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Segment Information (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Net Revenue by Geographical Area |
a) The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Income from Operations by Geographical Area |
b) The distribution of income from operations, including
restructuring, by geographical area was as follows:
c) The
distribution of income from operations, excluding restructuring, by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Property, Plant and Equipment, Net, by Geographical Area |
d) The distribution of property, plant and equipment, net, by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Depreciation and Amortization by Geographical Area |
e) The distribution of depreciation and amortization by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Total Assets by Geographical Area |
f) The distribution of total assets by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Operating Income by Geography. No definition available.
|
| X | ||||||||||
- Definition Schedule Of Depreciation And Amortization Expense By Geographical Area. No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Goodwill (Detail) - USD ($) $ in Thousands |
9 Months Ended | 12 Months Ended |
|---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
|
| Goodwill [Line Items] | ||
| Opening balance | $ 616,088 | $ 588,434 |
| Current period acquisitions (Note 3) | 129,072 | 34,576 |
| Prior period acquisitions (Note 3) | 1,393 | 7,689 |
| Foreign exchange movement | 17,824 | (14,611) |
| Closing balance | $ 764,377 | $ 616,088 |
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Additional payments made in respect of working capital review of net assets at acquisition. No definition available.
|
| X | ||||||||||
- Definition Number of Clinical Research Sites Acquired No definition available.
|
| X | ||||||||||
- Definition Number of Patients No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Mapi Group (Detail) - USD ($) $ in Thousands |
9 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Jul. 27, 2017 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
Dec. 31, 2015 |
||||||
| Business Acquisition [Line Items] | ||||||||||
| Goodwill | $ 764,377 | $ 616,088 | $ 588,434 | |||||||
| Total consideration | $ 144,131 | $ 54,009 | ||||||||
| Mapi Group [Member] | ||||||||||
| Business Acquisition [Line Items] | ||||||||||
| Cash | $ 18,634 | |||||||||
| Property, plant and equipment | 3,196 | |||||||||
| Goodwill | [1] | 129,072 | ||||||||
| Intangible assets | [2] | 30,637 | ||||||||
| Accounts receivable | 14,167 | |||||||||
| Unbilled revenue | 11,818 | |||||||||
| Prepayments and other current assets | 4,458 | |||||||||
| Other receivables | 2,379 | |||||||||
| Income taxes receivable | 2,799 | |||||||||
| Accounts payable | (3,184) | |||||||||
| Payments on account | (28,851) | |||||||||
| Other liabilities | (28,814) | |||||||||
| Non-current other liabilities | (1,061) | |||||||||
| Non-current deferred tax liability | (1,966) | |||||||||
| Net assets acquired | 153,284 | |||||||||
| Cash outflows | 144,131 | |||||||||
| Assessment of valuation of contingent consideration at acquisition | 9,153 | |||||||||
| Total consideration | $ 153,284 | |||||||||
| ||||||||||
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Income Taxes Receivable No definition available.
|
| X | ||||||||||
- Definition Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Receivables No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Payments on Account No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Mapi Group (Parenthetical) (Detail) $ in Thousands |
Jul. 27, 2017
USD ($)
|
|||
|---|---|---|---|---|
| Mapi Group [Member] | ||||
| Business Acquisition [Line Items] | ||||
| Intangible asset | $ 30,637 | [1] | ||
| ||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Fair Values of Assets Acquired and Liabilities Assumed of Clinical Research Management, Inc. (Detail) - USD ($) $ in Thousands |
9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Sep. 15, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Jun. 30, 2017 |
Mar. 31, 2017 |
Dec. 31, 2016 |
Dec. 31, 2015 |
|||
| Business Acquisition [Line Items] | |||||||||
| Goodwill | $ 764,377 | $ 616,088 | $ 588,434 | ||||||
| Total consideration | $ 144,131 | $ 54,009 | |||||||
| Clinical Research Management Inc. | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Cash | $ 3,168 | ||||||||
| Property, plant and equipment | 939 | ||||||||
| Goodwill | [1] | 35,969 | |||||||
| Accounts receivable | 11,431 | ||||||||
| Unbilled revenue | 3,868 | ||||||||
| Prepayments and other current assets | 1,673 | ||||||||
| Accounts payable | (165) | ||||||||
| Other liabilities | (5,569) | ||||||||
| Non-current other liabilities | (7) | ||||||||
| Net assets acquired | 58,396 | ||||||||
| Cash outflows (including other liabilities assumed of $9.2 million) | 52,396 | ||||||||
| Assessment of valuation of contingent consideration at acquisition | 6,000 | $ 0 | $ 6,000 | ||||||
| Total consideration | 58,396 | ||||||||
| Clinical Research Management Inc. | Order Backlog | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Intangible assets | 1,668 | ||||||||
| Clinical Research Management Inc. | Customer Lists | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Intangible assets | 4,012 | ||||||||
| Clinical Research Management Inc. | Brand | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Intangible assets | $ 1,409 | ||||||||
| |||||||||
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Fair Values of Assets Acquired and Liabilities Assumed of Clinical Research Management, Inc. (Parenthetical) (Detail) $ in Millions |
Sep. 15, 2016
USD ($)
|
|---|---|
| Clinical Research Management Inc. | |
| Business Acquisition [Line Items] | |
| Other liabilities assumed | $ 9.2 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Detail) - USD ($) $ in Thousands |
9 Months Ended | 13 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Dec. 04, 2015 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
Dec. 31, 2015 |
|||
| Business Acquisition [Line Items] | |||||||
| Goodwill | $ 764,377 | $ 616,088 | $ 588,434 | ||||
| Total cash outflows | $ 144,131 | $ 54,009 | |||||
| PMG | |||||||
| Business Acquisition [Line Items] | |||||||
| Cash | $ 194 | ||||||
| Property, plant and equipment | 712 | ||||||
| Goodwill | [1] | 48,728 | |||||
| Accounts receivable | 11,597 | ||||||
| Prepayments and other current assets | 1,329 | ||||||
| Accounts payable | (530) | ||||||
| Other liabilities | (3,456) | ||||||
| Non-current deferred tax liability | (3,106) | ||||||
| Net assets acquired | 65,354 | ||||||
| Cash consideration | 53,681 | $ 1,600 | |||||
| Other liabilities assumed | 10,060 | ||||||
| Working capital adjustment | 1,613 | ||||||
| Total cash outflows | 65,354 | ||||||
| PMG | Customer Lists | |||||||
| Business Acquisition [Line Items] | |||||||
| Intangible assets | 6,938 | ||||||
| PMG | Order Backlog | |||||||
| Business Acquisition [Line Items] | |||||||
| Intangible assets | $ 2,948 | ||||||
| |||||||
| X | ||||||||||
- Definition Additional payments made in respect of working capital review of net assets at acquisition. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Parenthetical) (Detail) - PMG - USD ($) $ in Thousands |
13 Months Ended | |
|---|---|---|
Dec. 04, 2015 |
Dec. 31, 2016 |
|
| Business Acquisition [Line Items] | ||
| Fair value adjustment to deferred tax liability | $ 3,100 | |
| Fair value adjustment to goodwill | 7,700 | |
| Fair value adjustment to accounts receivable | 1,400 | |
| Fair value adjustment to other liabilities | 1,200 | |
| Cash consideration | $ 53,681 | 1,600 |
| Customer list and order backlog | ||
| Business Acquisition [Line Items] | ||
| Fair value adjustment to intangible assets | $ 400 |
| X | ||||||||||
- Definition Represents final adjustment (as defined) to other liabilities acquired in connection with a business combination. No definition available.
|
| X | ||||||||||
- Definition Represents final adjustment (as defined) to deferred tax liabilities acquired in connection with a business combination. No definition available.
|
| X | ||||||||||
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to goodwill acquired in connection with a business combination for which the initial accounting was incomplete. No definition available.
|
| X | ||||||||||
- Definition Represents final adjustment (as defined) to accounts receivable acquired in connection with a business combination. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Detail) - USD ($) $ in Thousands |
Feb. 27, 2015 |
Sep. 30, 2017 |
Dec. 31, 2016 |
Dec. 31, 2015 |
|||||
|---|---|---|---|---|---|---|---|---|---|
| Business Acquisition [Line Items] | |||||||||
| Goodwill | $ 764,377 | $ 616,088 | $ 588,434 | ||||||
| MediMedia Pharma Solutions | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Property, plant and equipment | $ 1,049 | ||||||||
| Goodwill | [1] | 92,084 | |||||||
| Accounts receivable | 5,240 | ||||||||
| Unbilled revenue | 4,324 | ||||||||
| Prepayments and other current assets | 621 | ||||||||
| Accounts payable | (749) | ||||||||
| Payments on account | (4,186) | ||||||||
| Deferred tax liability | (2,171) | ||||||||
| Other liabilities | (5,483) | ||||||||
| Net assets acquired | 116,002 | ||||||||
| Cash consideration | 108,717 | ||||||||
| Other liabilities assumed | [2] | 11,283 | |||||||
| Gross cash outflows | 120,000 | ||||||||
| Working capital adjustment | (3,998) | ||||||||
| Net cash outflows | 116,002 | ||||||||
| MediMedia Pharma Solutions | Customer Lists | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Intangible asset | 22,752 | ||||||||
| MediMedia Pharma Solutions | Order Backlog | |||||||||
| Business Acquisition [Line Items] | |||||||||
| Intangible asset | $ 2,521 | ||||||||
| |||||||||
| X | ||||||||||
- Definition Additional payments made in respect of working capital review of net assets at acquisition. No definition available.
|
| X | ||||||||||
- Definition Business Combination, Consideration Transferred, Gross No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Payments on Account No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as current. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Parenthetical) (Detail) $ in Thousands |
Feb. 27, 2015
USD ($)
|
|||
|---|---|---|---|---|
| MediMedia Pharma Solutions | ||||
| Business Acquisition [Line Items] | ||||
| Other liabilities assumed | $ 11,283 | [1] | ||
| ||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Restructuring - Additional Information (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | 12 Months Ended | |
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
|
| Restructuring Cost and Reserve [Line Items] | ||||
| Restructuring charges | $ 4,065 | $ 7,753 | $ 8,159 | |
| Resource Rationalizations | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Restructuring charges | 0 | $ 8,159 | ||
| Other liabilities | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Restructuring Reserve,current | 5,600 | |||
| Non-current other liabilities | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Restructuring Reserve, Noncurrent | $ 500 | |||
| Onerous Lease | Resource Rationalizations | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Restructuring charges | 1,969 | |||
| Workforce Reduction | Resource Rationalizations | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Restructuring charges | $ 6,190 | |||
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Details of restructuring charge recognized (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | $ 4,065 | $ 7,753 | $ 8,159 |
| Total | $ 4,065 | $ 7,753 | $ 8,159 |
| X | ||||||||||
- Definition Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
Details of Movement in Restructuring Provisions Recognized (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Restructuring Cost and Reserve [Line Items] | |||
| Initial restructuring charge recorded | $ 4,065 | $ 7,753 | $ 8,159 |
| Cash payments | (2,536) | ||
| Foreign exchange movement | 0 | ||
| Closing provision | $ 5,217 | ||
| X | ||||||||||
- Definition Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Restructuring Charges (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | 12 Months Ended | |
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
|
| Restructuring Cost and Reserve [Line Items] | ||||
| Total provision recognized | $ 4,065 | $ 7,753 | $ 8,159 | |
| Foreign exchange | 0 | |||
| Closing provision | 5,217 | |||
| Resource Rationalizations | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Total provision recognized | 0 | $ 8,159 | ||
| Utilized | (1,150) | (6,305) | ||
| Foreign exchange | (63) | |||
| Closing provision | 641 | 1,791 | ||
| Workforce Reduction | Resource Rationalizations | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Total provision recognized | 6,190 | |||
| Utilized | (393) | (5,734) | ||
| Foreign exchange | (63) | |||
| Closing provision | 393 | |||
| Onerous Lease | Resource Rationalizations | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Total provision recognized | 1,969 | |||
| Utilized | (757) | (571) | ||
| Closing provision | $ 641 | $ 1,398 | ||
| X | ||||||||||
- Definition Restructuring Reserve Utilizations No definition available.
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Income Taxes Recognized During Period (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Reconciliation of Provision of Income Taxes [Line Items] | ||||
| Provision for income taxes before restructuring and other items | $ 8,239 | $ 10,979 | $ 31,414 | $ 31,669 |
| Tax impact of restructuring and other items | (509) | (969) | (1,020) | |
| Provision for income taxes after restructuring and other items | $ 8,239 | $ 10,470 | $ 30,445 | $ 30,649 |
| X | ||||||||||
- Definition Income Tax Expense Benefit Before Restructuring And Other Items No definition available.
|
| X | ||||||||||
- Definition Reconciliation of Provision of Income Taxes [Line Items] No definition available.
|
| X | ||||||||||
- Definition Tax Impact Of Restructuring And Other Items No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Income Taxes - Additional Information (Detail) - USD ($) $ in Millions |
9 Months Ended | |
|---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
|
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
| Liability for unrecognized tax benefit | $ 27.7 | $ 29.9 |
| Items generating unrecognized tax benefits | 24.1 | 26.6 |
| Interest and related penalties | $ 3.6 | $ 3.3 |
| Earliest Tax Year | ||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
| Tax year subject to examination by major tax jurisdictions | 2012 | |
| Latest Tax Year | ||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
| Tax year subject to examination by major tax jurisdictions | 2016 |
| X | ||||||||||
- Definition Unrecognized Tax Benefits, Current Year Tax Positions No definition available.
|
| X | ||||||||||
- Definition Tax year that remains open to examination under enacted tax laws, in CCYY format. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of unrecognized tax benefits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail) - shares |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] | ||||
| Weighted average number of ordinary shares outstanding for basic net income per ordinary share | 54,109,566 | 55,734,773 | 54,110,022 | 55,355,020 |
| Effect of dilutive share options outstanding | 646,618 | 910,466 | 730,090 | 1,120,299 |
| Weighted average number of ordinary shares outstanding for diluted net income per ordinary share | 54,756,184 | 56,645,239 | 54,840,112 | 56,475,319 |
| X | ||||||||||
- Definition Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] No definition available.
|
| X | ||||||||||
- Definition The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Share-based Awards - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions |
9 Months Ended | 12 Months Ended | 57 Months Ended | |||
|---|---|---|---|---|---|---|
Feb. 14, 2017 |
May 11, 2015 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
Sep. 30, 2017 |
|
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Non-cash stock compensation expense not yet recognized | $ 60.6 | $ 60.6 | ||||
| Unrecognized stock-based compensation expense, weighted average period (years) | 2 years 2 months 12 days | |||||
| Restricted Stock Units (RSUs) | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Fair value of stock units vested | $ 15.9 | $ 10.8 | ||||
| Stock units granted | 183,301 | |||||
| Performance Share Unit (PSUs) | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Fair value of stock units vested | $ 15.0 | $ 10.3 | ||||
| Stock units granted | 87,794 | |||||
| PSUs Based on Service and EPS Targets | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Stock units granted | 274,628 | |||||
| PSUs Based on Service and EPS Targets | Minimum | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Cumulative EPS vesting period | 2014 | |||||
| PSUs Based on Service and EPS Targets | Maximum | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Stock units to be granted | 262,993 | 262,993 | ||||
| Cumulative EPS vesting period | 2020 | |||||
| Employee Stock Plan, 2008 Plan | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | 6,000,000 | ||||
| Employee Stock Plan, 2008 Plan | Individual Employee | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Ordinary shares which have been reserved for issuance | 400,000 | 400,000 | ||||
| Employee Stock Plan, 2008 Plan | Minimum | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Additional number of ordinary shares which have been reserved for issuance | 400,000 | |||||
| Percentage of option price for fair value of ordinary share | 100.00% | |||||
| Employee Stock Plan, 2008 Plan | Maximum | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Additional number of ordinary shares which have been reserved for issuance | 1,000,000 | |||||
| Employee Stock Plan, 2003 Plan | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | 6,000,000 | ||||
| Maximum number of award as percentage of shares outstanding | 10.00% | |||||
| Employee Stock Plan, 2003 Plan | Individual Employee | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Ordinary shares which have been reserved for issuance | 400,000 | 400,000 | ||||
| Employee Stock Option | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Shares vesting period | 5 years | |||||
| Shares expiration period | 8 years | |||||
| Weighted average contractual term of options outstanding | 4 years 11 months 19 days | |||||
| Weighted average fair value per option | $ 11.56 | |||||
| Exercisable - number of shares | 612,869 | 612,869 | ||||
| Exercisable - weighted average remaining contractual life | 3 years 8 months 16 days | |||||
| Exercisable - weighted average exercise price | $ 39.86 | $ 39.86 | ||||
| Fully vested total intrinsic value | $ 45.4 | $ 45.4 | ||||
| Intrinsic value of option exercised | $ 21.8 | $ 12.5 | ||||
| Employee Stock Option | Minimum | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Options outstanding fair value | $ 8.53 | $ 8.53 | ||||
| Employee Stock Option | Maximum | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Weighted average contractual term of options outstanding | 8 years | |||||
| Options outstanding fair value | $ 25.99 | $ 25.99 | ||||
| Restricted Stock Units 2008 | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Ordinary shares which have been reserved for issuance | 1,000,000 | 1,000,000 | ||||
| Restricted Stock Units 2013 | ||||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||
| Additional number of ordinary shares which have been reserved for issuance | 2,500,000 | |||||
| Ordinary shares which have been reserved for issuance | 4,100,000 | |||||
| X | ||||||||||
- Definition Compensation Related Costs Share Based Payments Disclosure [Line Items] No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Weighted Average Option Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Option Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award Other Than Options Expected Vesting Period No definition available.
|
| X | ||||||||||
- Definition Unrecognized cost of unvested share-based compensation awards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of additional shares authorized for issuance under an established share-based compensation plan. No definition available.
|
| X | ||||||||||
- Definition The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. No definition available.
|
| X | ||||||||||
- Definition Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Purchase price of common stock expressed as a percentage of its fair value. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Stock Option Activity (Detail) - Employee Stock Option - $ / shares |
9 Months Ended | |
|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Options Outstanding Number of Shares | ||
| Outstanding at beginning of period | 1,466,444 | |
| Granted | 219,113 | |
| Exercised | (321,685) | |
| Forfeited | (49,579) | |
| Outstanding at end of period | 1,314,293 | |
| Exercisable at end of period | 612,869 | |
| Weighted Average Exercise Price | ||
| Outstanding at beginning of period | $ 43.45 | |
| Granted | 85.98 | |
| Exercised | 24.19 | |
| Forfeited | 53.65 | |
| Outstanding at end of period | 54.87 | |
| Exercisable at end of period | 39.86 | |
| Weighted Average Fair Value | ||
| Outstanding at beginning of period | 13.94 | |
| Granted | 25.06 | $ 20.10 |
| Exercised | 9.19 | |
| Forfeited | 16.58 | |
| Outstanding at end of period | 16.86 | |
| Exercisable at end of period | $ 13.25 | |
| Weighted Average Remaining Contractual Life | ||
| Outstanding at end of period | 4 years 11 months 19 days | |
| Exercisable at end of period | 3 years 8 months 16 days | |
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Forfeited in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract] No definition available.
|
| X | ||||||||||
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Abstract] No definition available.
|
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. No definition available.
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Movement in Non-Vested Share Options (Detail) - Employee Stock Option - $ / shares |
9 Months Ended | |
|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Options Outstanding Number of Shares | ||
| Beginning Balance | 814,870 | |
| Granted | 219,113 | |
| Vested | (290,600) | |
| Forfeited | (41,959) | |
| Ending Balance | 701,424 | |
| Weighted Average Exercise Price | ||
| Beginning balance | $ 54.37 | |
| Granted | 85.98 | |
| Vested | 44.61 | |
| Forfeited | 59.31 | |
| Ending balance | 67.99 | |
| Weighted Average Fair Value | ||
| Beginning Balance | 16.55 | |
| Granted | 25.06 | $ 20.10 |
| Vested | 14.40 | |
| Forfeited | 17.87 | |
| Ending Balance | $ 20.02 | |
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Forfeited in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Exercise Price Abstract No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of non-vested options outstanding. No definition available.
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Number of non-vested options forfeited. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options forfeited. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of options vested. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of options vested. No definition available.
|
| X | ||||||||||
- Details
|
Schedule of Weighted Average Fair Values and Assumptions Used (Detail) - Employee Stock Option - $ / shares |
9 Months Ended | |
|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
| Weighted average fair value | $ 25.06 | $ 20.10 |
| Assumptions: | ||
| Expected volatility | 29.00% | 30.00% |
| Dividend yield | 0.00% | 0.00% |
| Risk-free interest rate | 1.93% | 1.39% |
| Expected life | 5 years | 5 years |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The risk-free interest rate assumption that is used in valuing an option on its own shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of RSU and PSU Activity (Detail) - $ / shares |
9 Months Ended | 12 Months Ended |
|---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
|
| Performance Share Unit (PSUs) | ||
| Outstanding Number of Shares | ||
| Outstanding at beginning of period | 830,523 | |
| Granted | 87,794 | |
| Shares vested | (320,640) | |
| Forfeited | (60,056) | |
| Outstanding at ending of period | 537,621 | 830,523 |
| Weighted Average Fair Value | ||
| Outstanding at beginning of period | $ 60.73 | |
| Granted | 84.10 | |
| Shares vested | 46.63 | |
| Forfeited | 66.67 | |
| Outstanding at end of period | $ 72.05 | $ 60.73 |
| Weighted Average Remaining Contractual Life | ||
| Outstanding at end of period | 1 year 2 months 5 days | 1 year 1 month 9 days |
| Restricted Stock Units (RSUs) | ||
| Outstanding Number of Shares | ||
| Outstanding at beginning of period | 1,025,484 | |
| Granted | 183,301 | |
| Shares vested | (353,243) | |
| Forfeited | (110,354) | |
| Outstanding at ending of period | 745,188 | 1,025,484 |
| Weighted Average Fair Value | ||
| Outstanding at beginning of period | $ 58.64 | |
| Granted | 88.63 | |
| Shares vested | 44.89 | |
| Forfeited | 62.91 | |
| Outstanding at end of period | $ 71.90 | $ 58.64 |
| Weighted Average Remaining Contractual Life | ||
| Outstanding at end of period | 1 year 6 months | 1 year 4 months 24 days |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Schedule of Non-cash Stock Compensation Expense (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 8,260 | $ 10,445 | $ 26,961 | $ 31,135 |
| Direct costs | ||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | 4,551 | 5,755 | 14,855 | 16,830 |
| Selling, general and administrative | ||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 3,709 | $ 4,690 | $ 12,106 | $ 14,305 |
| X | ||||||||||
- Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Share Capital - Additional Information (Detail) - USD ($) |
9 Months Ended | ||
|---|---|---|---|
Sep. 30, 2017 |
Oct. 03, 2016 |
Sep. 30, 2017 |
|
| Equity, Class of Treasury Stock [Line Items] | |||
| Ordinary shares repurchased | 2,797,323 | 1,368,136 | |
| Ordinary shares repurchased, value | $ 218,100,000 | $ 108,100,000 | |
| Buyback Program | |||
| Equity, Class of Treasury Stock [Line Items] | |||
| Stock repurchase program, authorized amount | $ 400,000,000 | ||
| Buyback Program | Maximum | |||
| Equity, Class of Treasury Stock [Line Items] | |||
| Share repurchase program, authorized percentage | 10.00% |
| X | ||||||||||
- Definition Stock Repurchase Program Authorized Percentage No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of stock repurchase plan authorized. No definition available.
|
| X | ||||||||||
- Definition Number of shares that have been repurchased during the period and are being held in treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Business Segment Information - Additional Information (Detail) |
9 Months Ended |
|---|---|
|
Sep. 30, 2017
Segment
| |
| Segment Reporting Information [Line Items] | |
| Number of operating segments | 1 |
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
Distribution of Net Revenue by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|||
| Segment Reporting Information [Line Items] | ||||||
| Net Revenue | $ 440,323 | $ 420,201 | $ 1,303,300 | $ 1,231,353 | ||
| Ireland | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Net Revenue | [1] | 107,820 | 97,299 | 312,916 | 293,787 | |
| Rest Of Europe | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Net Revenue | 89,536 | 76,427 | 239,447 | 231,505 | ||
| United States | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Net Revenue | 192,947 | 204,265 | 600,640 | 581,732 | ||
| Rest of World | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Net Revenue | $ 50,020 | $ 42,210 | $ 150,297 | $ 124,329 | ||
| ||||||
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution Income from Operations, including Restructuring, by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Segment Reporting Information [Line Items] | ||||
| Income from operations | $ 84,938 | $ 77,114 | $ 248,594 | $ 227,051 |
| Ireland | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 62,152 | 63,933 | 164,760 | 178,081 |
| Rest Of Europe | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 2,526 | 837 | 15,124 | 9,144 |
| United States | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 16,150 | 11,471 | 52,897 | 34,081 |
| Rest of World | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | $ 4,110 | $ 873 | $ 15,813 | $ 5,745 |
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution Income from Operations, excluding Restructuring, by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | $ 84,938 | $ 81,179 | $ 256,347 | $ 235,210 |
| Ireland | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | 62,152 | 64,821 | 172,513 | 182,698 |
| Rest Of Europe | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | 2,526 | 1,364 | 15,124 | 9,979 |
| United States | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | 16,150 | 13,813 | 52,897 | 36,423 |
| Rest of World | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | $ 4,110 | $ 1,181 | $ 15,813 | $ 6,110 |
| X | ||||||||||
- Definition Operating Income Loss Before Restructuring Charges No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail) - USD ($) $ in Thousands |
Sep. 30, 2017 |
Dec. 31, 2016 |
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 152,305 | $ 148,967 |
| Ireland | ||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 101,941 | 105,684 |
| Rest Of Europe | ||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 8,827 | 6,231 |
| United States | ||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 26,073 | 29,428 |
| Rest of World | ||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 15,464 | $ 7,624 |
| X | ||||||||||
- Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Depreciation and Amortization by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | $ 16,280 | $ 14,543 | $ 45,123 | $ 44,120 |
| Ireland | ||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | 6,985 | 6,588 | 19,465 | 19,146 |
| Rest Of Europe | ||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | 3,469 | 1,730 | 6,498 | 5,265 |
| United States | ||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | 4,819 | 5,368 | 16,348 | 17,154 |
| Rest of World | ||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | $ 1,007 | $ 857 | $ 2,812 | $ 2,555 |
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Total Assets by Geographical Area (Detail) - USD ($) $ in Thousands |
Sep. 30, 2017 |
Dec. 31, 2016 |
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Assets | $ 2,053,349 | $ 1,825,843 |
| Ireland | ||
| Segment Reporting Information [Line Items] | ||
| Assets | 797,019 | 766,120 |
| Rest Of Europe | ||
| Segment Reporting Information [Line Items] | ||
| Assets | 512,827 | 337,062 |
| United States | ||
| Segment Reporting Information [Line Items] | ||
| Assets | 633,065 | 651,160 |
| Rest of World | ||
| Segment Reporting Information [Line Items] | ||
| Assets | $ 110,438 | $ 71,501 |
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|